 The DIAS study Part 2 was performed to support the dose finding of desmoteplase treatment in subjects with acute ischemic stroke selected by perfusiondiffusion mismatch on MRI within a time window of 3 to 9 h after stroke-symptom onset. In addition, it assessed safety and tolerability of 3 doses of desmoteplase compared with placebo with special consideration of intracranial hemorrhage and major systemic bleedings. 